April 10, 2015
On behalf of IFARA, Liz Highleyman spoke with an international group of doctors about liver-related issues in HIV treatment. Each doctor is involved in a different study related to hepatitis C (HCV), but all agreed on the importance of affordable treatment for the disease. As Dr. Dore put it, "the affordable aspect of therapy is key."
The studies discussed were the ION-4 trial of sofosbuvir/ledipasvir (Harvoni) and the ALLY-2 trial, which combines sofosbuvir (Sovaldi) with daclatasvir. Very high sustained virologic responses of around 96% for a 12-week course of treatment were achieved in both clinical trials.
Historically, hemophiliacs have responded poorly to traditional HCV therapy because their bodies often contain a mixed population of the virus. A recent study showed this subpopulation to respond better to treatment with telaprevir (Incivek), pegylated interferon and ribavirin than to standard therapy.
The importance of treatment access was emphasized by a modeling study, which found that the mortality rate of HIV/HCV coinfected patients doubles, if the treatment of liver-related complications is delayed until the patient's liver disease has reached stage 3.
Two ongoing Australian projects are looking at the impact of a rapid scale-up of HCV treatment on HCV transmission rates. One of the projects is studying a prison population, and the other HIV-positive men who have sex with men.
Linking hard-to-treat populations to care is now one of the most pressing issues besides affordable treatment, Dr. Wyles believed.
Watch the video to learn more:
About the panelists:
The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.
[CORRECTION 4/16: An earlier version of this article incorrectly identified the two trials that were discussed. We have corrected the names of the trials to ION-4 and ALLY-2 from IL-4 and IL-2.]
Barbara Jungwirth is a freelance writer and translator based in New York.
Follow Barbara on Twitter: @reliabletran.
Copyright © 2015 Remedy Health Media, LLC. All rights reserved.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|HIV Providers and Advocates Continue to Debate STI Rates in the Era of PrEP and U=U|
|On-Demand PrEP Is Great. Now, What About Women?|
|High Rates of Anal HPV Infection in Gay Men Using PrEP in IPERGAY: The Role of Vaccination|
|Alberta Clinic Explores Long-Term Survival Among HIV-Positive People|
|Potential New Targets to Block HIV Latency|